Could a cancer drug slow MS progression? new trial halted midway
Disease control
Terminated
This phase 3 trial tests whether the oral drug masitinib can slow disability worsening in people with progressive multiple sclerosis who do not have relapses. About 800 participants will receive either masitinib or a placebo for 96 weeks. The main goal is to see if masitinib dela…
Phase: PHASE3 • Sponsor: AB Science • Aim: Disease control
Last updated Jun 27, 2026 12:29 UTC